Last updated: May 27, 2026
FANAPT (iloperidone) commercial supply is built around (1) iloperidone API sourcing, (2) formulation and finished-dose manufacturing for oral tablets, and (3) packaging and distribution. A complete supplier map requires shipment-level evidence tied to the specific NDA holder and each commercial labeler listed for U.S. market supply. If that link is not available in the record set being used, a complete, accurate supplier answer cannot be produced.
What companies supply iloperidone API for FANAPT?
A reliable “API suppliers for FANAPT” answer depends on primary documentation that identifies the API manufacturer(s) used for marketed batches (for example, FDA drug substance listing detail for the iloperidone API, Certificate of Analysis metadata that names the manufacturer, or validated commercial supply agreements tied to the NDA/ANDA record). Without those primary identifiers, listing API vendors would be speculative.
Which contract manufacturers make FANAPT tablets (finished dose)?
A “finished-dose supplier” answer requires: (i) the finished-dose manufacturer(s) shown in FDA labeling or listing systems for the marketed presentation, and (ii) batch manufacturing attribution for marketed NDCs. Without NDC-specific manufacturer attribution, any supplier list risks being wrong.
Who packages and distributes FANAPT in the U.S. market?
Packaging and distribution suppliers are typically tied to the labeler and the NDC-specific supply chain. Producing a correct supplier list requires NDC-labeler and repackager/wholesaler evidence. Without NDC-level sourcing details, an accurate supplier map cannot be produced.
How do you find the real FANAPT suppliers from FDA listings (Orange Book, SPL, labeling)?
A defensible approach links the U.S. marketed product to:
- SPL/NDC labeler and responsible party
- Drug substance listing identifiers for iloperidone
- Manufacturer-of-record for finished dosage forms in the SPL
- Current labeling “Manufactured for/Distributed by” lines for the specific NDC
If those elements are not present in the provided record set, supplier identification cannot be completed.
What dosage forms and strengths affect the supplier list for FANAPT?
Supplier mapping must be presentation-specific. FANAPT is an oral tablet product; the manufacturer-of-record can vary by strength, packaging configuration, and lifecycle (site changes, tech transfers, and post-approval changes). A complete supplier answer requires matching each strength/NDC to its commercial manufacturing site.
Do generic or authorized alternatives change supplier risk for FANAPT sourcing?
Generic and authorized alternatives can draw from different API and manufacturing networks. Without knowing the FANAPT NDC-specific commercial supply chain, you cannot quantify sourcing concentration risk or compare it with competitor supply.
How can supply-chain concentration affect FANAPT availability and pricing?
Supply risk analysis needs batch manufacturing concentration and component sourcing dependence. Without supplier attribution tied to marketed batches, concentration metrics cannot be stated.
Key Takeaways
- A complete, accurate list of “suppliers for FANAPT” requires NDC-specific manufacturing attribution plus iloperidone API drug-substance identifiers used in marketed batches.
- Without that primary linkage, naming specific API, tablet CMO, packaging, or distribution suppliers would be speculative.
FAQs
- Which companies are listed as manufacturers on FANAPT’s current U.S. labeling for each NDC?
- What iloperidone API drug substance listings appear for FANAPT in FDA SPL data?
- Do FANAPT tablet strengths have different finished-dose manufacturers or packaging sites?
- How do site transfers or manufacturing changes show up in postmarketing FDA submissions for FANAPT?
- How can you reconcile Orange Book listing ownership with actual commercial manufacturing sites?
References (APA)
No sources were cited because no supplier-identifying record set was provided.
